Business News • PR NewsWire • BerGenbio's Bemcentinib Meets Primary Endpoint in First Cohort of Phase 2 NSCLC Study in Combination With Keytruda®

BerGenbio's Bemcentinib Meets Primary Endpoint in First Cohort of Phase 2 NSCLC Study in Combination With Keytruda®

BerGenbio's Bemcentinib Meets Primary Endpoint in First Cohort of Phase 2 NSCLC Study in Combination With Keytruda®

OSLO, Nov. 6, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces today that the primary endpoint of Overall Response Rate (ORR) has been met in Cohort A of...

View More : https://www.prnewswire.com:443/news-releases/bergenbios-bemcentinib-meets-primary-endpoint-in-first-cohort-of-phase-2-ns...

Releted News by prnewswire